GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.
GENinCode has raised $5.1M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2023.
GENinCode's investors include Maven Capital Partners.
GENinCode is headquartered in Oxford, United Kingdom.
GENinCode is a genetic testing business specializing in the risk assessment and prediction of cardiovascular disease.
GENinCode is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"GENinCode — Funding & Investors." VCBacked, December 21, 2023, https://www.vcbacked.co/company/genincode. Accessed August 13, 2026.
VCBacked. (2023). GENinCode — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/genincode
{{cite web |title=GENinCode — Funding & Investors |url=https://www.vcbacked.co/company/genincode |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated